中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2359 records (took 0.074 seconds)

    Ex vivo modifiable medicament release-associations
    373.
    发明申请
    Ex vivo modifiable medicament release-associations 审中-公开
    离体可修饰的药物释放关联

    公开(公告)号：US20100068278A1

    公开(公告)日：2010-03-18

    申请号：US12387328

    申请日：2009-04-29

    Applicant: Mahalaxmi Gita Bangera ,  Edward S. Boyden ,  Roderick A. Hyde ,  Muriel Y. Ishikawa ,  Dennis J. Rivet ,  Elizabeth A. Sweeney ,  Lowell L. Wood, JR. ,  Victoria Y.H. Wood

    Inventor： Mahalaxmi Gita Bangera ,  Edward S. Boyden ,  Roderick A. Hyde ,  Muriel Y. Ishikawa ,  Dennis J. Rivet ,  Elizabeth A. Sweeney ,  Lowell L. Wood, JR. ,  Victoria Y.H. Wood

    IPC: A61K9/14

    CPC classification number: G06F19/3456 ,  A61K9/06 ,  A61K9/127 ,  A61K9/4891 ,  A61K9/51

    Abstract: Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a medicament, and a substance associated with the medicament in a first release-control state. In the first release-control state, the medicament has a first bioavailability to the animal. The substance is modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal. The final dosage form also includes another medicament, and another substance associated with the another medicament in another first release-control state. In the another first release-control state, the another medicament has another first bioavailability to the animal. The another substance is modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability.

    Abstract translation: 描述的实施方案包括最终剂型，制品和方法。 所描述的最终剂型包括药物和与第一释放 - 控制状态的药物相关的物质。 在第一释放控制状态下，药物对动物具有第一生物利用度。 该物质可通过暴露于第二释放 - 控制状态下的药物的刺激而离体修饰，其中所述药物对动物具有第二生物利用度。 最终剂型还包括另一种药物，以及另一种与另一种药物在另一种第一释放 - 控制状态相关的物质。 在另一个第一释放控制状态中，另一种药物对动物具有另一种第一生物利用度。 另一种物质可以通过暴露于另一种刺激而在另一种第二释放 - 控制状态下与另一种药物接触而离体修饰，其中另一种药物具有另一种第二生物利用度。

    Individualizable dosage form
    375.
    发明申请
    Individualizable dosage form 审中-公开
    可个性化的剂型

    公开(公告)号：US20100068235A1

    公开(公告)日：2010-03-18

    申请号：US12284015

    申请日：2008-09-16

    Applicant: Mahalaxmi Gita Bangera ,  Edward S. Boyden ,  Roderick A. Hyde ,  Muriel Y. Ishikawa ,  Dennis J. Rivet ,  Elizabeth A. Sweeney ,  Lowell L. Wood, JR. ,  Victoria Y.H. Wood

    Inventor： Mahalaxmi Gita Bangera ,  Edward S. Boyden ,  Roderick A. Hyde ,  Muriel Y. Ishikawa ,  Dennis J. Rivet ,  Elizabeth A. Sweeney ,  Lowell L. Wood, JR. ,  Victoria Y.H. Wood

    IPC: A61K9/24 ,  A61K8/02

    CPC classification number: A61K9/28 ,  A61K9/0009 ,  G06F19/3462

    Abstract: Provided embodiments include a final dosage form, an article of manufacture, and a method. A final dosage form for delivering a medicament to an animal is provided. The final dosage form includes an outer layer. The final dosage form also includes a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to a stimulus. The final dosage form further includes a chamber at least substantially within the outer layer and configured to carry the medicament. The final dosage form further includes a containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal. The final dosage form includes the medicament. The final dosage form may include an indicator element configured to indicate an exposure of the release element to the stimulus.

    Abstract translation: 所提供的实施方案包括最终剂型，制品和方法。 提供了用于将药物递送至动物的最终剂型。 最终剂型包括外层。 最终剂型还包括配置在第一药物释放状态中的释放元件，并且在体外暴露于刺激物时可修改为第二药物释放状态。 最终剂型还包括至少基本上在外层内并且构造成携带药物的腔室。 最终剂型还包括构造成将药物保持在最终剂型中直到将该剂型施用于动物的容纳元件。 最终剂型包括药物。 最终剂型可以包括指示元件，其被配置为指示释放元件暴露于刺激。

Patent Agency Ranking